A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

Key Inclusion Criteria: Physician-diagnosed immunoglobulin E (IgE) mediated peanut allergy; Peanut specific serum IgE measured by ImmunoCAP® ≥ 0.7 kilounit allergy specific antibody per litre (kUA/L) at screening; Positive skin prick test to peanut with mean wheal diameter ≥5 mm greater than negative control at screening; Positive peanut double blind placebo-controlled food challenge (DBPCFC) with a reactive dose ≤300 mg peanut protein (≤443 mg cumulative reactive dose [CRD]); Able to perform spirometry or peak expiratory flow. Children who are 4 years of age at Screening Stage 1 visit and unable to perform peak expiratory may be enrolled providing they had no clinical features of moderate or severe persistent asthma within 1 year prior to the Screening visit; Forced expiratory volume in 1 second (FEV1) ≥80% predicted in adolescents and children with asthma capable of performing spirometry, or peak expiratory flow ≥80% predicted in participants with asthma unable to perform spirometry (at investigator's discretion). Key Exclusion Criteria: History of or current clinically significant medical conditions or laboratory abnormalities which in the opinion of the investigator would jeopardise the safety of the participant or the validity of the study results; Severe or unstable asthma as assessed by the Global Initiative for Asthma (GINA) assessment of asthma control OR current treatment for asthma at GINA ≥Step 4 level; Participants with skin disorders that would hinder skin prick testing and/or its interpretation or study drug administration (eg, severe generalised poorly controllable atopic dermatitis); Any medical condition in which epinephrine (adrenaline) is contraindicated; Prior therapy aimed at desensitising peanut allergy, either in a formal study or in clinical practice; Severe or life-threatening reaction during the screening food challenge, at investigator discretion.